Lincoln Pharmaceuticals Ltd (LINCOLN) AI Stock Analysis

1 Followers

Lincoln Pharmaceuticals Ltd

(NSE:LINCOLN)

Select Model

Rating:70Outperform

Price Target:INR 563.00▲(9.73% Upside)

Action:reiterated

Date:10/30/26

The score is driven primarily by strong financial strength (low leverage, solid profitability, and improved FY2026 cash flow) and a reasonable P/E valuation. These positives are tempered by weak technicals, with the stock trading below major moving averages and negative MACD signaling poor near-term momentum.

Positive Factors

Very Low LeverageExtremely low leverage materially limits debt-related financial risk and preserves flexibility for investment, product development, and market expansion. The growing equity base provides resilience if operating conditions weaken, while avoiding substantial interest burdens that could otherwise reduce future profitability.

Negative Factors

Margin CompressionBroad-based margin compression indicates that higher costs or a weaker product mix are absorbing part of the benefit from revenue growth. If this persists, earnings may expand more slowly than sales and the company could have less operating capacity to fund investment or withstand pricing pressure.

Lincoln Pharmaceuticals Ltd (LINCOLN) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 10.32B
Dividend Yield: 0.35%
Average Volume (3M): 3,952
Price to Earnings (P/E): 10.6
Beta (1Y): 1.12
Revenue Growth: 10.20%
EPS Growth: 11.70%
Country: India
Employees: 1,352
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Lincoln Pharmaceuticals Ltd Business Overview & Revenue Model

Company Description

Lincoln Pharmaceuticals Limited, established in 1979 and headquartered in Ahmedabad, India, is a pharmaceutical company engaged in the manufacturing and global distribution of its products. Its comprehensive product line addresses a wide array of med...

Lincoln Pharmaceuticals Ltd Financial Statement Overview

Summary

Strong overall fundamentals supported by steady revenue growth (6.1% in FY2026), healthy net margin (~13.1%), and very conservative leverage (debt-to-equity ~0.006). Offsetting factors include notable margin compression versus FY2024–FY2025 and historically uneven cash conversion, despite a sharp FY2026 free-cash-flow improvement (~0.82B).

Income Statement

74Positive

Balance Sheet

90Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	7.19B	6.71B	6.23B	5.81B	5.05B	4.68B
Gross Profit	2.87B	2.20B	3.32B	2.97B	2.59B	2.46B
EBITDA	1.29B	1.31B	1.24B	1.34B	1.12B	1.05B
Net Income	964.53M	878.94M	823.46M	933.05M	728.99M	693.55M
Balance Sheet
Total Assets	0	8.90B	7.97B	7.00B	5.87B	5.34B
Cash, Cash Equivalents and Short-Term Investments	2.41B	2.41B	1.96B	1.52B	1.14B	1.15B
Total Debt	0	44.22M	0	10.67M	19.97M	20.44M
Total Liabilities	-7.58B	1.33B	1.25B	1.07B	849.46M	1.01B
Stockholders Equity	7.58B	7.58B	6.72B	5.93B	5.02B	4.33B
Cash Flow
Free Cash Flow	390.02M	815.07M	737.71M	237.41M	249.80M	306.07M
Operating Cash Flow	497.63M	1.07B	930.15M	632.17M	392.62M	761.32M
Investing Cash Flow	-422.12M	-996.37M	-789.47M	-573.42M	-366.43M	-780.80M
Financing Cash Flow	-6.86M	8.16M	-64.02M	-51.80M	-45.01M	-25.56M

Lincoln Pharmaceuticals Ltd Technical Analysis

Technical Analysis SentimentNegative

Last Price513.10

Price Trends

50DMA576.90Negative

100DMA591.41Negative

200DMA592.44Negative

Market Momentum

MACD-18.75Positive

RSI39.43Neutral

STOCH25.10Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LINCOLN, the sentiment is Negative. The current price of 513.10 is below the 20-day moving average (MA) of 533.69, below the 50-day MA of 576.90, and below the 200-day MA of 592.44, indicating a bearish trend. The MACD of -18.75 indicates Positive momentum. The RSI at 39.43 is Neutral, neither overbought nor oversold. The STOCH value of 25.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:LINCOLN.

Lincoln Pharmaceuticals Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:LINCOLN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:JAGSNPHARM	78Outperform	INR 14.32B	32.68	―	1.80%	11.71%	-26.92%
IN:SYNCOMF	75Outperform	INR 17.94B	22.59	―	0.49%	0.44%	48.60%
IN:LINCOLN	70Outperform	INR 10.10B	10.60	―	0.35%	10.20%	11.70%
IN:VENUSREM	69Neutral	INR 17.63B	15.17	―	0.73%	20.22%	73.03%
IN:WANBURY	56Neutral	INR 6.74B	11.13	―	―	3.63%	24.22%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:INDSWFTLAB	51Neutral	INR 29.81B	37.97	―	―	66.39%	-72.31%

* General Sector Average

Performance Comparison

IN:LINCOLN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:LINCOLN	Lincoln Pharmaceuticals Ltd	513.10	-10.96	-2.09%
IN:INDSWFTLAB	Ind-Swift Laboratories Ltd.	371.65	271.00	269.25%
IN:JAGSNPHARM	Jagsonpal Pharmaceuticals Ltd.	221.80	9.26	4.36%
IN:SYNCOMF	Syncom Formulation (India) Ltd.	20.56	4.57	28.57%
IN:VENUSREM	Venus Remedies Limited	1384.95	938.97	210.54%
IN:WANBURY	Wanbury Limited	192.55	-54.35	-22.01%

Lincoln Pharmaceuticals Ltd Corporate Events

Lincoln Pharmaceuticals sets September 30 virtual AGM, proposes dividend and director re-appointments

Sep 5, 2026

Lincoln Pharmaceuticals Ltd has scheduled its 32nd Annual General Meeting for September 30, 2026, at 11:00 a.m. IST, to be conducted via video conferencing or other audio-visual means, with the registered office in Ahmedabad deemed as the venue. The...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 30, 2026

Lincoln Pharmaceuticals Ltd AI Stock Analysis